New drug cocktail shows promise for advanced liver cancer
NCT ID NCT07267806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding chemotherapy to a two-drug combination (camrelizumab and apatinib) helps people with advanced liver cancer live longer without their disease getting worse. About 326 adults with liver cancer that cannot be removed by surgery will participate. The goal is to find a more effective first-line treatment option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY EFFECT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict chemo brain before it happens?
- Virtual reality vs. relaxing videos: a new weapon against chemo side effects?
- Biopsy DNA clues could spare esophageal cancer patients from futile chemo
- Hypnosis may ease Chemotherapy's toll on breast cancer patients
- Could a common anesthetic help prevent liver cancer from coming back?
- Simple gel may prevent painful side effect of liver cancer drug